Xyloct spray 35mkg / dose, 15ml

Acute respiratory diseases with symptoms of rhinitis (runny nose), acute allergic rhinitis, hay fever, sinusitis, eustachitis, otitis media (to reduce swelling of the nasopharyngeal mucosa).

Preparing the patient for diagnostic manipulations in the nasal passages.

Intranasally (in each nasal passage).

Children aged 2 to 6 years: 1 injection, nasal spray dosed 35 mcg / dose in each nasal passage;

should not be applied more than 3 times a day.

If symptoms worsen or do not improve within 3 days, you should consult your doctor. In the recommended dose, without consulting a doctor, use for no more than 7 days.

Doses higher than recommended can only be used under medical supervision. With frequent and prolonged use of the drug, the feeling of 'stuffiness' in the nose may reappear or worsen. If these symptoms appear, you should stop treatment and consult a doctor.

1 dose (70 ?l) of the drug contains:

Active substance: Xylometazoline hydrochloride -35 ?g

Excipients: Benzalkonium chloride - 7.0 ?g Disodium edetate (Trilon B) - 35.0 ?g Sodium hydrogen phosphate dihydrate - 140.0 ?g Sodium dihydrogen phosphate dihydrate - 140.0 ?g Sodium chloride - 518.0 ?g Water for injection - 69, 4 mg

- Hypersensitivity to the components of the drug;

- Arterial hypertension;

- Tachycardia;

- Severe atherosclerosis;

- Glaucoma;

- Atrophic rhinitis;

- Thyrotoxicosis;

- Surgical interventions on the meninges (in history);

- Conditions after transsphenoidal hypophysectomy;

- Children under 2 years of age - for SOLOxylometazoline, nasal spray dosed at 35 mcg / dose;

- Pregnancy.

Do not use during therapy with monoamine oxidase inhibitors and tricyclic antidepressants (including a period of 14 days after their withdrawal).

Carefully

Diabetes mellitus, prostatic hyperplasia, ischemic heart disease (angina pectoris), pheochromocytoma, hyperthyroidism, lactation period; with hypersensitivity to adrenergic drugs, accompanied by insomnia, dizziness, arrhythmia, tremor, increased blood pressure.

pharmachologic effect

Xylometazoline belongs to the group of local vasoconstrictor agents (decongestants) with a 2-adrenomimetic effect. It has a quick, pronounced and prolonged vasoconstrictor effect on the vessels of the nasal mucosa, thus eliminating its swelling and hyperemia. Restores the patency of the nasal passages, facilitates nasal breathing with rhinitis.

In therapeutic concentrations, it does not irritate the mucous membrane of the nasal cavity, does not cause hyperemia. The action begins in a few minutes and lasts for 10-12 hours.

Pharmacokinetics

When applied topically, it is practically not absorbed, plasma concentrations are so small that they cannot be determined by modern analytical methods.

Side effects

With frequent and / or prolonged use - irritation and / or dryness of the nasopharyngeal mucosa, burning, tingling, sneezing, hypersecretion of the nasopharyngeal mucosa, hypersensitivity reactions, swelling of the nasal mucosa, palpitations, tachycardia, arrhythmia, increased blood pressure, headache , nausea, vomiting, insomnia, visual impairment, depression (with prolonged use of high doses).

If any of the side effects indicated in the instructions are aggravated or you notice any other side effects not listed in the instructions, inform your doctor.

Interaction

Xylometazoline should not be used in patients receiving therapy with monoamine oxidase inhibitors and tricyclic antidepressants (including a period of 14 days after their withdrawal) due to the possibility of increased blood pressure.

Overdose

Symptoms: increased side effects (dose-dependent), decreased body temperature, confusion. In case of accidental ingestion, the drug can cause: severe dizziness, increased sweating, headache, bradycardia, increased blood pressure, respiratory depression, coma and convulsions. After an increase in blood pressure, a sharp decrease can be observed.

Treatment: symptomatic.